CytoMed Therapeutics Ltd. (GDTC): Price and Financial Metrics

CytoMed Therapeutics Ltd. (GDTC): $2.10

0.01 (-0.24%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add GDTC to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

NR

Ranked

#NR of NR

in industry

GDTC Price/Volume Stats

Current price $2.10 52-week high $9.25
Prev. close $2.11 52-week low $1.92
Day low $2.10 Volume 800
Day high $2.13 Avg. volume 31,645
50-day MA $2.29 Dividend yield N/A
200-day MA $3.42 Market Cap 22.97M

GDTC Stock Price Chart Interactive Chart >



GDTC Latest News Stream


Event/Time News Detail
Loading, please wait...

GDTC Latest Social Stream


Loading social stream, please wait...

View Full GDTC Social Stream

Latest GDTC News From Around the Web

Below are the latest news stories about CYTOMED THERAPEUTICS LTD that investors may wish to consider to help them evaluate GDTC as an investment opportunity.

One CytoMed Therapeutics Insider Raised Stake By 46% In Previous Year

From what we can see, insiders were net buyers in CytoMed Therapeutics Limited's ( NASDAQ:GDTC ) during the past 12...

Yahoo | December 21, 2023

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc.,

Yahoo | December 5, 2023

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced its first half of 2023 financial results and provided clinical and corporate updates.

Yahoo | November 17, 2023

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.

Yahoo | November 14, 2023

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies ...

Yahoo | October 24, 2023

Read More 'GDTC' Stories Here

GDTC Price Returns

1-mo -1.41%
3-mo N/A
6-mo -38.89%
1-year -47.50%
3-year N/A
5-year N/A
YTD -57.14%
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!